Division of Pfizer Inc.
Latest From Medivation Inc.
Astellas’s Xtandi gets its latest approval in China, where Merck’s Keytruda is set for another win.
Secondary endpoint assessing cardiovascular risk may offer important differentiation from AbbVie’s Lupron. Myovant accelerated the prostate cancer filing soon after slowing the planned relugolix submission for uterine fibroids.
Former Medivation CEO David Hung launched stealthy oncology start-up Nuvation with $275m in series A venture capital, while Tenaya's series B brought in $92m for small molecules as well as cell and gene therapies to treat cardiovascular diseases.
The former Medivation CEO, after a brief detour heading up Axovant, is returning to oncology, but the new company is keeping details about the seven cancer drug programs in its pipeline under wraps.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Pfizer Inc.
- Senior Management
David T Hung, MD, Pres. & CEO
Jennifer Jarrett, CFO
Joseph Lobacki, Chief Commercial Officer
Marion McCourt, COO
- Contact Info
Phone: (415) 543-3470
525 Market St.
San Francisco, CA 94105
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.